Secondary prevention in coronary heart disease: baseline survey of provision in general practice.
OBJECTIVE
To determine secondary preventive treatment and habits among patients with coronary heart disease in general practice.


METHODS
Process of care data on a random sample of patients were collected from medical records. Health and lifestyle data were collected by postal questionnaire (response rate 71%).


METHODS
Stratified, random sample of general practices in Grampian.


METHODS
1921 patients aged under 80 years with coronary heart disease identified from pre-existing registers of coronary heart disease and nitrate prescriptions.


METHODS
Treatment with aspirin, beta blockers, and angiotensin converting enzyme inhibitors. Management of lipid concentrations and hypertension according to local guidelines. Dietary habits (dietary instrument for nutritional evaluation score), physical activity (health practice indices), smoking, and body mass index.


RESULTS
825/1319 (63%) patients took aspirin. Of 414 patients with recent myocardial infarction, 131 (32%) took beta blockers, and of 257 with heart failure, 102 (40%) took angiotensin converting enzyme inhibitors. Blood pressure was managed according to current guidelines for 1566 (82%) patients but lipid concentrations for only 133 (17%). 673 of 1327 patients (51%) took little or no exercise, 245 of 1333 (18%) were current smokers, 808 of 1264 (64%) were overweight, and 627 of 1213 (52%) ate more fat than recommended.


CONCLUSIONS
In terms of secondary prevention, half of patients had at least two aspects of their medical management that were suboptimal and nearly two thirds had at least two aspects of their health behaviour that would benefit from change. There seems to be considerable potential to increase secondary prevention of coronary heart disease in general practice.
Campbell
N C
NC
Department of General Practice and Primary Care, University of Aberdeen, Foresterhill Health Centre, Aberdeen AB25 2AY. n.campbell@abdn.ac.uk
Thain
J
J
Deans
H G
HG
Ritchie
L D
LD
Rawles
J M
JM
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001794:Blood Pressure; D003327:Coronary Disease / Q000517:prevention & control*; D004032:Diet; D015444:Exercise; D015438:Health Behavior; D006293:Health Promotion; D006801:Humans; D006937:Hypercholesterolemia / Q000517:prevention & control; D006973:Hypertension / Q000517:prevention & control; D008019:Life Style; D008875:Middle Aged; D009566:Nitrates / Q000627:therapeutic use; D012309:Risk-Taking; D012606:Scotland; D016540:Smoking Cessation
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D009566:Nitrates; D001241:Aspirin